ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2014
In Vivo Labeling of Serum Albumin for PET.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 83 citations in OpenAlex.
- Microsurgery guided by sequential preoperative lymphography usingEuropean journal of nuclear medicine and molecular imaging · 2017Trial
- Albumin Nanoparticles as Multifunctional Carriers for Advanced Therapeutics.Pharmaceutics · 2026Review
- Development of new albumin-binding radiotracers for PET imaging of cerebrospinal fluid flow in the glymphatic system.EJNMMI radiopharmacy and chemistry · 2025Article
- Sultones for Radiofluorination and Bioconjugation: Fluorine-18 Labeling of Native Proteins and Glycoproteins.ACS omega · 2025Article
- Tissue-seeking dyes for in vivo applications.Smart molecules : open access · 2024Review
- Thyroid Cancers Exhibit Oncogene-Enhanced Macropinocytosis that Is Restrained by IGF1R and Promote Albumin-Drug Conjugate Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Preclinical PET Imaging and Toxicity Study of aPharmaceutics · 2023Article
- Novel albumin-binding multifunctional probe for synergistic enhancement of FL/MR dual-modal imaging and photothermal therapy.Frontiers in chemistry · 2023Article
- Radiolabeled albumin through SRSC advances · 2022Article
- Article
- RelatingPhysics in medicine and biology · 2022Article
- A Comparison of Evans Blue and 4-(Pharmaceutics · 2022Article
- Dual Function of aFrontiers in cardiovascular medicine · 2022Article
- Article
- Multi-Scale Imaging of Vascular Pathologies in Cardiovascular Disease.Frontiers in medicine · 2021Review
- [EJNMMI research · 2020Article
- 68Ga-NEB PET/CT can be a new method for diagnosing chylous fistula: Case reports of a rare complication after breast cancer surgery.Medicine · 2020Article
- A pocket-escaping design to prevent the common interference with near-infrared fluorescent probes in vivo.Nature communications · 2020Article
- Recent trends in protein and peptide-based biomaterials for advanced drug delivery.Advanced drug delivery reviews · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
unlabelledThe purpose of this study was to develop a novel in vivo albumin-labeling method to allow PET of cardiac function after myocardial infarction and vascular leakage and increased permeability in inflammatory diseases and malignant tumors.
methodsTo label albumin in vivo, we synthesized a NOTA (1,4,7-triazacyclononane-N,N',N″-triacetic acid)-conjugated truncated form of Evans blue (NEB). (18)F labeling was achieved by the formation of an (18)F-aluminum fluoride ((18)F-AlF) complex, and (64)Cu labeling was obtained by a standard chelation method. Sixty-minute dynamic PET imaging was performed on normal mice to evaluate the distribution of (18)F-AlF-NEB, which was compared with in vitro-labeled mouse serum albumin ((18)F-fluorobenzyl-MSA). Electrocardiography-gated PET imaging was performed in a mouse model of myocardial infarction. Both dynamic and static PET scans were obtained in a mouse inflammation model induced by local injection of turpentine to evaluate vascular leakage. Tumor permeability was studied by dynamic and late-point static PET using (64)Cu-NEB in a UM-22B xenograft model.
resultsNEB was successfully synthesized, and (18)F labeling including work-up took about 20-30 min, with a radiochemical purity greater than 95% without the need for high-performance liquid chromatography purification. Most of the radioactivity was retained in the circulation system at 60 min after injection (26.35 ± 1.52 percentage injected dose per gram [%ID/g]). With electrocardiography-gated PET, ventricles of the heart and major arteries were clearly visualized. The myocardial infarction mice showed much lower left ventricular ejection fraction than the control mice. Inflammatory muscles showed significantly higher tracer accumulation than the contralateral healthy ones. UM-22B tumor uptake of (64)Cu-NEB gradually increased with time (5.73 ± 1.11 %ID/g at 1 h and 8.03 ± 0.77 %ID/g at 2 h after injection).
conclusionThe distribution and local accumulation of serum albumin can be noninvasively visualized and quantified by (18)F-AlF-NEB and (64)Cu-NEB PET. The simple labeling and broad applications make these imaging probes attractive for clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.